Form PTO-1449 INFORMAT II (Us	ION N AR	N DISCLOSUR DCITA N APPLICATION eral sheets if necessary) APR 1	1 2006 Wu Filing	et Number (Optional) S-044.01 icant cherpfennig et al. 3 Date / 11, 2003 S. PATENT DOCUMENTS		Application No. 10/617,565 Group Art Unit 1743	8	Sheetrap	,
EXAMINER INITIAL	D	OCUMENT NUMBER	DATE	NAME	CLAS	s sue	BCLASS	FILING DA	
MD	A2,	5,869,270	02/09/99	Rhode et al.					
					·			-	
			FOR	EIGN PATENT DOCUMEN	NTS				
	D	OCUMENT NUMBER	DATE	COUNTRY	CLAS	s su	BCLASS	Translati YES	on NO
							:		
		OTI	HER DOCUM	IENTS ,	(Including	Author, Title,	Date, Per	tinent Pages Etc	:.)
MD	C35			ol Change in the Human Major H Chemistry, 38:5878-5887 (1999)	istocompatib	ility Compl	ex Protir	HLA-DR1	

/Marianne Dibrino/

02/16/2007

02/19/2007

orm PTO-1449	<u> </u>		Docket Number (Optional)	——————————————————————————————————————	Sheet Page 2 of 3 Application Number
INFORM		N DISCLOSURE CITATION	DFS-044.01	,	10/617,568
IN AN APPLICATION (Use several sheets if necessary)			Applicant Wucherpfennig et al.		
	(036 364	erui sneeis y necessury)	Filing Date		Group Art Unit
		,	July 11, 2003		1743 1644
MD 	C10	Halder et al., "Isolation of No Line FM3 ¹ ," Cancer Res., 5°	ovel HLA-DR Restricted Poter 7:3238-3244 (1997)	ntial Turnor-associated	d Antigens from the Melanoma Cell
	CH		s and Allele-Specific Anchors	in HLA-DR-Binding	Peptides," Cell, 74:197-203 (1993)
	C12	Hausmann et al., "pH-depend Release of CLIP at an Endos	dent Peptide Binding Propertie omal pH," J. Exp. Med., 189:1	s of the Type I Diabet 723-1733 (1999)	tes-associated I-A ⁸⁷ Molecule: Rapid
	C13	Jensen et al., "Long-lived Co Low pH with No Requireme	omplexes between Peptide and nt for pH Neutralization," J. Ex	Class II Major Histoc kp. Med., 176:793-798	compatibility Complex Are Formed at 8 (1992)
	C14		on of Recombinant HLA-DR2	Molecules," J. Biol. C	Chem., 271:20156-20162 (1996)
	C15	Kozono et al., Production of 154 (1994)	soluble MHC class II proteins	with covalently bound	d single peptides," Nature, 369:151-
	C16	a Monoclonal Antibody Spec	tion of Myelin Basic Protein (Poific for the Human Histocomp (8):1395-1412 (4/20	atibility Leukocyte A	s in Multiple Sclerosis Lesions using ntigen (HLA)-DR2-MBP 85-99
	C17	Kwok et al., "HLA-DQ Tetra		c T Cells in Periphera	l Blood of Herpes Simplex Virus ponsive Cells ¹ ," J. Immuno.,
	C18	Lanzavecchia et al., "Irrevers 357:249-252 (1992)	sible association of peptides wi	th class II MHC mole	cules in living cells," Nature,
	C19	Lee et al., "Structure of a hur Immunol., 2:501-507 (2001)	nan insulin peptide-HLA-DQ8	complex and suscept	ibility to type I diabetes," Nat.
	C20	Malcherek et al., "Supermotif Histocompatibility Complex-	fs Enable Natural Invariant Cha Class II Molecules," J. Exp. Mo	nin-derived Peptides to ed., 181:527-536 (199	o Interact with Many Major (5)
	C21	Matsui et al., "Kinetics of T-c T-cell responsiveness," Proc.	cell receptor binding to peptide Natl. Acad. Sci., USA, 91:128	e/I-E ^k complexes: Con 362-12866 (1994).	relation of the dissociation rate with
	C22	Meyer et al., "Direct enumera Natl. Acad. Sci., USA, 97:11	ation of Borrelia-reactive CD4 433-11438 (2000)	T Cells ex vivo by us	ing MHC class II tetramers," Proc.
	C23	Murali-Krishna et al., "Count Infection," Immunity, 8:177-	ting Antigen-Specific CD8 T C 187 (1998)	Cells: A Reevaluation	of Bystander Activation during Viral

Novak et al., "MHC class II tetramers identify peptide-specific human CD4⁺ T cells proliferating in response to

02/19/2007

c24 influenza A antigen," J. Clin. Invest., 104:R63-67 (1999)

/Marianne Dibrino/

MD

EXAMINER

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)			Docket Number (Optional) DFS-044.01		Application Number 10/617,568			
			Applicant Wucherpfennig et al.					
·		,,,,	Filing Date		Group Art Unit	4.1		
<u></u>	_	Riberdy et al., "HLA-DR mol-	July 11, 2003	essing mutant cell line a		44		
MD	C25				ic associated with invaria	ant cham		
	C26	Rosenberg et al., "Vigorous HIV-1-Specific CD4 ⁺ T Cell Responses Associated with Control of Viremia," Science, 278:1447-1450 (1997)						
	C27	Savage et al., "A Kinetic Basis For T Cell Receptor Repertoire Selection during an Immune Response," Immunity, 10:485-492 (1999)						
	C28	Scott et al., "Role of Chain Pairing for the Production of Functional Soluble IA Major Histocompatibility Complex Class II Molecules," J. Exp. Med., 183:2087-2095 (1996)						
	C29	Stern, L.J. and Wiley, D.C., "The Human Class II MHC Protein HLA-DR1 Assembles as Empty αβ Heterodimers in the Absence of Antigenic Peptide," Cell, 68:465-477(1992)						
	C30	Valli et al., "Binding of Myelin Basic Protein Peptides to Human Histocompatibility Leukocyte Antigen Class II Molecules and Their Recognition by T Cells from Multiple Sclerosis Patients," J. Clin. Invest., 91:616-628 (1993)						
	C31	Vonderheide et al., "Equivalent Induction of Telomerase-specific Cytotoxic T Lymphocytes from Tumor-bearing Patients and Healthy Individuals," Cancer Res., 61:8366-8370 (2001)						
	C32	Wucherpfennig et al., "Structural Requirements for Binding of an Immunodominant Myelin Basic Protein Peptide to DR2 Isotypes and for Its Recognition by Human T Cell Clones," J. Exp. Med., 179:279-290 (1994)						
	C33	Yu et al., "Binding of conserved islet peptides by human and murine MHC class II molecules associated with susceptibility to type I diabetes," Eur. J. Immunol., 30:2497-2506 (2000)						
MD	C34	Zarutskie et al., "The kinetic basis of peptide exchange catalysis by HLA-DM," PNAS, 98(22):12450-12455						
EXAMINER		/Marianne D	Dibrino/		02/19/2007			